Your browser doesn't support javascript.
loading
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.
da Silva, Ines Pires; Ahmed, Tasnia; Reijers, Irene L M; Warner, Allison Betof; Patrinely, James Randall; Serra-Bellver, Patricio; Allayous, Clara; Mangana, Joanna; Zimmer, Lisa; Trojaniello, Claudia; Klein, Oliver; Gerard, Camille L; Michielin, Olivier; Haydon, Andrew; Ascierto, Paolo A; Carlino, Matteo S; Lebbe, Celeste; Lorigan, Paul; Johnson, Douglas B; Sandhu, Shahneen; Lo, Serigne N; Menzies, Alexander M; Long, Georgina V.
Affiliation
  • da Silva IP; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Westmead and Blacktown Hospitals, Sydney, NSW, Australia.
  • Ahmed T; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia.
  • Reijers ILM; The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Warner AB; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Patrinely JR; Vanderbilt University Medical Center, Nashville, TN, USA.
  • Serra-Bellver P; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
  • Allayous C; AP-HP Dermatology, INSERM U976, Université de Paris, Saint Louis Hospital, Paris, France.
  • Mangana J; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
  • Zimmer L; Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Trojaniello C; Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Napoli, Italy.
  • Klein O; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.
  • Gerard CL; Oncology Department, Lausanne University Hospital, Lausanne, Switzerland.
  • Michielin O; Oncology Department, Lausanne University Hospital, Lausanne, Switzerland.
  • Haydon A; Department of Medical Oncology, Alfred Hospital, Monash University, Melbourne, VIC, Australia.
  • Ascierto PA; Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Napoli, Italy.
  • Carlino MS; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Westmead and Blacktown Hospitals, Sydney, NSW, Australia.
  • Lebbe C; AP-HP Dermatology, INSERM U976, Université de Paris, Saint Louis Hospital, Paris, France.
  • Lorigan P; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Services, The University of Manchester, Manchester, UK.
  • Johnson DB; Vanderbilt University Medical Center, Nashville, TN, USA.
  • Sandhu S; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Lo SN; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia.
  • Menzies AM; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.
  • Long GV; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia. Electronic address: georgina.long@melanoma.org.au.
Lancet Oncol ; 22(8): e343-e344, 2021 08.
Article in En | MEDLINE | ID: mdl-34339647
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Melanoma Limits: Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2021 Document type: Article Affiliation country: Australia
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Melanoma Limits: Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2021 Document type: Article Affiliation country: Australia